76 related articles for article (PubMed ID: 9401829)
1. The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers.
Hantson L; Tritsmans L; Crabbé R; Gheuens J; Van Rooy P
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):491-5. PubMed ID: 9401829
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.
Van de Velde V; Crabbe R; Van Peer A; Woestenborghs R; Van Osselaer N; Hantson L; Heykants J
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):490-3. PubMed ID: 9760010
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of lubeluzole (Prosynap(R)) in patients with ischemic stroke.
Hacke W; Lees KR; Timmerhuis T; Haan J; Hantson L; Hennerici M; Diener HC
Cerebrovasc Dis; 1998; 8(5):247-54. PubMed ID: 9712921
[TBL] [Abstract][Full Text] [Related]
4. Effects of the antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording.
Sugiyama A; Ni C; Arita J; Eto K; Xue YX; Hashimoto K
Toxicol Appl Pharmacol; 1996 Jul; 139(1):109-14. PubMed ID: 8685892
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of the neuroprotective drug lubeluzole in patients with ischemic stroke.
De Keyser J; Van de Velde V; Schellens RL; Hantson L; Tritsmans L; Gheuens J; Van Peer A; Woestenborghs R; Franke CL; van Gorp J
Clin Ther; 1997; 19(6):1340-51. PubMed ID: 9444444
[TBL] [Abstract][Full Text] [Related]
8. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
9. Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers.
Herron J; Lee P; Pesco-Koplowitz L; Gajjar D; Soo YW; Woestenborghs R
Clin Ther; 1998; 20(4):682-90. PubMed ID: 9737828
[TBL] [Abstract][Full Text] [Related]
10. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
14. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
15. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
[TBL] [Abstract][Full Text] [Related]
16. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
18. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
RodrĂguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
20. Multiple-dose, double-blind, placebo controlled intravenous tolerance and pharmacokinetic study of trospectomycin sulfate (U-63, 366F) in healthy male volunteers.
Peters GR; Novak E; Batts DH; Bye A; Nichols DJ; Francom SF
Int J Clin Pharmacol Ther Toxicol; 1990 Sep; 28(9):361-8. PubMed ID: 2146231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]